Her-2

Description:

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer free. This is the biography of Her-2, Herceptin, the drug that provoked dramatic responses in Barbara and other women in the trials that offers promise for hundreds of thousands of women.

subjects: HER-2 gene,  Breast,  Cancer,  Trastuzumab,  HER-2 protein,  Immunotherapy,  New York Times reviewed,  Breast, cancer,  Cancer, treatment,  Cancer, immunotherapy,  Monoclonal antibodies,  Breast Neoplasms,  Therapy,  Therapeutic use,  Borstkanker,  Gentherapie,  Drug therapy